Create Free Account

By creating account you will get access to hot stocks & personalised emails

Medlab Clinical Ltd

Healthcare AU MDC

NoneAUD
-(-%)

Last update at 2024-01-11T05:45:08.394428Z

Day Range

--
LowHigh

52 Week Range

6.608.10
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap15.07M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.13350M
  • Revenue TTM1.54M
  • Revenue Per Share TTM0.67
  • Gross Profit TTM 1.20M
  • Diluted EPS TTM-547.5

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-06-30 2021-06-30 2020-06-30 2019-06-30 2018-06-30
Type yearly yearly yearly yearly yearly
Date 2022-06-30 2021-06-30 2020-06-30 2019-06-30 2018-06-30
Income before tax -8.38845M -12.40283M -13.48832M -8.17410M -4.75820M
Minority interest 0.07M -0.23856M -0.14186M -0.05706M -1.02036M
Net income -7.16243M -12.32371M -13.39937M -8.09094M -4.57040M
Selling general administrative 7.31M 8.12M 6.86M 6.97M 4.54M
Selling and marketing expenses 0.19M 0.77M 1.75M 1.53M 0.65M
Gross profit 0.95M 1.46M 0.04M 2.37M 2.12M
Reconciled depreciation 0.85M 0.87M 0.96M 0.15M 0.11M
Ebit -8.34375M -12.34554M -13.29103M -8.09432M -4.51544M
Ebitda -7.49244M -11.47205M -12.33003M -7.94683M -4.40308M
Depreciation and amortization 0.85M 0.87M 0.96M 0.15M 0.11M
Non operating income net other - - - - -
Operating income -0.01298M -0.01323M -0.01337M -0.00843M -6.11019M
Other operating expenses 0.00920M 0.01M 0.00882M 0.00767M 10.25M
Interest expense 0.04M 0.06M 0.20M 0.08M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.04M 0.14M 0.20M 0.08M 0.05M
Net interest income -0.05719M -0.11387M -0.19729M 0.26M 0.11M
Extraordinary items 1.16M 2.77M - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 3.52M 3.68M 3.00M 2.31M 0.00000M
Total revenue 1.28M 4.40M 2.85M 5.43M 4.14M
Total operating expenses 13.98M 17.45M 16.30M 13.12M 8.23M
Cost of revenue 0.34M 2.94M 2.80M 3.06M 2.02M
Total other income expense net 4.70M 3.70M 2.89M 2.32M 1.35M
Discontinued operations 1.16M 1.16M 1.16M 1.16M -
Net income from continuing ops -8.38845M -12.40283M -13.48832M -8.17410M -4.75820M
Net income applicable to common shares -7.16243M -12.32371M -13.39937M -8.09094M -4.57040M
Preferred stock and other adjustments - - - - -
Breakdown 2022-06-30 2021-06-30 2020-06-30 2019-06-30 2018-06-30
Type yearly yearly yearly yearly yearly
Date 2022-06-30 2021-06-30 2020-06-30 2019-06-30 2018-06-30
Total assets 11.37M 20.65M 17.79M 20.20M 24.33M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.00300M 0.07M 0.15M 1.62M 0.26M
Total liab 3.62M 5.74M 6.53M 5.21M 2.47M
Total stockholder equity 8.08M 15.14M 11.40M 15.05M 22.88M
Deferred long term liab - - - - -
Other current liab 0.00194M 0.00355M 0.00260M 0.00243M 0.86M
Common stock 66.81M 66.81M 51.36M 41.62M 39.16M
Capital stock 66.81M 66.81M 51.36M 41.62M -
Retained earnings -59.52909M -52.36666M -40.04295M -26.64358M -16.35330M
Other liab 0.19M 0.23M 0.48M 0.23M 0.12M
Good will - - - - -
Other assets 0.71M 0.48M 0.48M 0.48M 0.07M
Cash 5.19M 13.43M 9.06M 11.44M 20.33M
Cash and equivalents - - 0.00000M 8.00M 20.33M
Total current liabilities 2.88M 4.52M 4.43M 4.98M 2.35M
Current deferred revenue 1.78M 2.33M 1.90M 1.46M -
Net debt -4.06824M -11.73969M -6.72922M -10.41460M -19.83299M
Short term debt 0.57M 0.71M 0.70M 0.97M 0.50M
Short long term debt - 0.07M 0.09M 0.97M 0.50M
Short long term debt total 1.12M 1.70M 2.33M 1.03M 0.50M
Other stockholder equity -0.00798M -0.01506M -0.01132M -0.01498M 0.07M
Property plant equipment 1.42M 2.08M 2.88M 0.63M 0.44M
Total current assets 9.24M 18.08M 14.42M 19.09M 23.81M
Long term investments 0.48M 0.48M 0.48M - -
Net tangible assets 8.08M 15.14M 11.40M 15.05M 22.88M
Short term investments 0.00035M 0.00024M - - -
Net receivables 3.87M 3.36M 3.38M 3.81M 2.06M
Long term debt - - - - 0.00000M
Inventory 0.08M 0.79M 1.47M 2.22M 1.16M
Accounts payable 0.53M 1.48M 1.82M 2.55M 0.99M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.80M 0.70M 0.08M 0.07M 0.07M
Additional paid in capital - - - - -
Common stock total equity - - 51.36M 41.62M 39.16M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.23M - - 0.48M 0.07M
Deferred long term asset charges - - - - -
Non current assets total 2.12M 2.57M 3.36M 1.11M 0.51M
Capital lease obligations 1.12M 1.63M 2.24M 0.06M -
Long term debt total 0.55M 0.99M 1.63M 0.00000M 0.00000M
Breakdown 2022-06-30 2021-06-30 2020-06-30 2019-06-30 2018-06-30
Type yearly yearly yearly yearly yearly
Date 2022-06-30 2021-06-30 2020-06-30 2019-06-30 2018-06-30
Investments 1.78M -0.08290M -0.24308M -0.34032M -0.09648M
Change to liabilities -1.52885M -0.22701M -0.78186M 1.68M 0.60M
Total cashflows from investing activities 1.75M -0.08290M -0.24308M -0.34032M -0.09648M
Net borrowings -0.72478M -0.63874M -1.51301M 0.47M 0.20M
Total cash from financing activities -0.72478M 14.81M 8.32M 1.78M 23.68M
Change to operating activities 0.37M 0.09M 1.67M -1.17203M 0.06M
Net income -0.00716M -0.01232M -0.01340M -0.00809M -4.57040M
Change in cash -8.24373M 4.37M -2.37893M -8.89072M 18.84M
Begin period cash flow 13.43M 9.06M 11.44M 20.33M 1.50M
End period cash flow 5.19M 13.43M 9.06M 11.44M 20.33M
Total cash from operating activities -0.00941M -0.01035M -0.01042M -0.01032M -4.77537M
Issuance of capital stock - 16.57M 10.40M 1.30M -
Depreciation 0.00085M 0.00087M 0.00096M 0.00015M 0.11M
Other cashflows from investing activities -0.00040M 0.00040M 0.00040M 0.00040M 0.00040M
Dividends paid 12.72M 2.78M 3.94M - -
Change to inventory -0.00007M 0.00068M 0.00074M -0.00105M -0.40298M
Change to account receivables -0.00002M -0.00026M 0.00043M -0.00176M -0.35508M
Sale purchase of stock -1.12419M -1.12419M -0.56330M 1.30M -1.32000M
Other cashflows from financing activities -0.65694M 4.94M 7.32M 6.12M 2.49M
Change to netincome -1.21791M 0.53M -0.05421M -0.07417M -0.21616M
Capital expenditures 0.03M 0.08M 0.24M 0.34M 0.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.00009M 0.00042M 0.00118M -0.00281M 1.07M
Stock based compensation 0.00008M 0.00062M - - -
Other non cash items -0.00310M 0.00110M 0.00084M 0.00044M 4.46M
Free cash flow -0.03802M -0.09365M -0.25350M -0.35064M -4.87184M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MDC
Medlab Clinical Ltd		 - -% - - - 9.81 1.86 8.58 -1.4685
CSL
CSL Ltd		 -3.45 1.22% 278.79 32.86 33.00 9.11 5.02 6.65 20.64
TLX
Telix Pharmaceuticals Ltd		 -0.07 0.27% 25.67 161.73 75.19 12.58 19.98 12.52 109.28
MSB
Mesoblast Ltd		 1.07 54.04% 3.05 - 454.55 312.43 2.49 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.36 2.79% 12.54 13.51 35.21 8.91 5.13 6.48 8.45

Reports Covered

Stock Research & News

View All

Profile

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery. In addition, it offers virtual clinic services. The company was founded in 2012 and is headquartered in Botany, Australia.

Medlab Clinical Ltd

Building A, Botany, NSW, Australia, 2019

Key Executives

Name Title Year Born
Dr. Sean Michael Hall MD, CEO & Director 1970
Mr. Kerem Kaya CFO, COO & Company Sec. 1973
Dr. David A. Rutolo ­ (USA), J.D., Ph.D. Director of Science NA
Mr. Ian Curtinsmith Chief Information Officer NA
Mr. Tony Potter Head of Pharmaceuticals NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.